Parallax Volatility Advisers’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.68M | Buy |
16,933
+3,299
| +24% | +$446K | ﹤0.01% | 741 |
|
|
2026
Q1 | $1.86M | Buy |
13,634
+13,633
| +1,363,300% | +$1.7M | ﹤0.01% | 803 |
|
|
2025
Q4 | $122 | Sell |
1
-194,819
| -100% | -$22.3M | ﹤0.01% | 1595 |
|
|
2025
Q3 | $19.5M | Buy |
194,820
+192,958
| +10,363% | +$17.4M | 0.03% | 296 |
|
|
2025
Q2 | $154K | Sell |
1,862
-13,478
| -88% | -$1.08M | ﹤0.01% | 1360 |
|
|
2025
Q1 | $1.24M | Sell |
15,340
-300,666
| -95% | -$26.9M | ﹤0.01% | 997 |
|
|
2024
Q4 | $28.5M | Buy |
316,006
+263,782
| +505% | +$25.6M | 0.06% | 280 |
|
|
2024
Q3 | $5.16M | Sell |
52,224
-119,957
| -70% | -$11.8M | 0.01% | 780 |
|
|
2024
Q2 | $16M | Buy |
172,181
+134,778
| +360% | +$12.1M | 0.03% | 343 |
|
|
2024
Q1 | $3.55M | Sell |
37,403
-199,509
| -84% | -$18.5M | 0.01% | 845 |
|
|
2023
Q4 | $21.2M | Buy |
236,912
+169,648
| +252% | +$12.6M | 0.04% | 376 |
|
|
2023
Q3 | $4.91M | Sell |
67,264
-65,483
| -49% | -$5.23M | 0.01% | 769 |
|
|
2023
Q2 | $11M | Sell |
132,747
-199,625
| -60% | -$16.7M | 0.02% | 502 |
|
|
2023
Q1 | $25.3M | Buy |
332,372
+332,369
| +11,078,967% | +$27.6M | 0.05% | 326 |
|
|
2022
Q4 | $249 | Sell |
3
-65,650
| -100% | -$5.31M | ﹤0.01% | 2781 |
|
|
2022
Q3 | $5.21M | Sell |
65,653
-538,490
| -89% | -$45.4M | 0.01% | 1005 |
|
|
2022
Q2 | $44.9M | Buy |
604,143
+409,199
| +210% | +$30.7M | 0.04% | 296 |
|
|
2022
Q1 | $17.5M | Buy |
194,944
+194,941
| +6,498,033% | +$18M | 0.01% | 562 |
|
|
2021
Q4 | $0 | Hold |
3
| – | – | ﹤0.01% | 3515 |
|
|
2021
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 3461 |
|
|
2021
Q2 | $0 | Sell |
3
-10,852
| -100% | -$1.43M | ﹤0.01% | 3621 |
|
|
2021
Q1 | $1.47M | Sell |
10,855
-254,654
| -96% | -$38.1M | ﹤0.01% | 1898 |
|
|
2020
Q4 | $37.4M | Buy |
265,509
+265,254
| +104,021% | +$34M | 0.03% | 539 |
|
|
2020
Q3 | $28K | Sell |
255
-11,704
| -98% | -$1.31M | ﹤0.01% | 2916 |
|
|
2020
Q2 | $1.34M | Sell |
11,959
-145,341
| -92% | -$14.3M | ﹤0.01% | 1624 |
|
|
2020
Q1 | $12.2M | Buy |
157,300
+128,714
| +450% | +$11.4M | 0.02% | 540 |
|
|
2019
Q4 | $2.72M | Sell |
28,586
-51,448
| -64% | -$4.45M | ﹤0.01% | 1143 |
|
|
2019
Q3 | $6.1M | Sell |
80,034
-40,596
| -34% | -$3.37M | 0.01% | 746 |
|
|
2019
Q2 | $10.6M | Sell |
120,630
-601
| -0.5% | -$51.3K | 0.01% | 507 |
|
|
2019
Q1 | $11M | Sell |
121,231
-168,995
| -58% | -$14.4M | 0.01% | 455 |
|
|
2018
Q4 | $20.8M | Buy |
290,226
+290,223
| +9,674,100% | +$23.4M | 0.03% | 333 |
|
|
2018
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 3732 |
|
|
2018
Q2 | $0 | Hold |
3
| – | – | ﹤0.01% | 3466 |
|
|
2018
Q1 | $0 | Hold |
3
| – | – | ﹤0.01% | 4435 |
|
|
2017
Q4 | $0 | Hold |
3
| – | – | ﹤0.01% | 5066 |
|
|
2017
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 3441 |
|
|
2017
Q2 | $0 | Sell |
3
-55,070
| -100% | -$3.91M | ﹤0.01% | 4207 |
|
|
2017
Q1 | $3.82M | Sell |
55,073
-308,928
| -85% | -$20.7M | 0.01% | 654 |
|
|
2016
Q4 | $21.5M | Buy |
364,001
+363,998
| +12,133,267% | +$22.5M | 0.04% | 256 |
|
|
2016
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 4080 |
|
|
2016
Q2 | $0 | Hold |
3
| – | – | ﹤0.01% | 3690 |
|
|
2016
Q1 | $0 | Hold |
3
| – | – | ﹤0.01% | 3846 |
|
|
2015
Q4 | $0 | Hold |
3
| – | – | ﹤0.01% | 4057 |
|
|
2015
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 4343 |
|
|
2015
Q2 | $0 | Hold |
3
| – | – | ﹤0.01% | 5099 |
|
|
2015
Q1 | $0 | Hold |
3
| – | – | ﹤0.01% | 5697 |
|
|
2014
Q4 | $0 | Sell |
3
-4,110
| -100% | -$234K | ﹤0.01% | 6003 |
|
|
2014
Q3 | $214K | Buy |
4,113
+3,609
| +716% | +$184K | ﹤0.01% | 2415 |
|
|
2014
Q2 | $26K | Buy |
+504
| New | +$22.7K | ﹤0.01% | 3346 |
|
Other funds holding XBI
JFG
Parallax Volatility Advisers's XBI Position: Q2 2026 in Review
Parallax Volatility Advisers increased its State Street SPDR S&P Biotech ETF (XBI) stake by 24% in Q2 2026, buying an estimated $446K and bringing the position to 16,933 shares worth $2.68M. The position accounts for ﹤0.01% of the portfolio, ranked #741.
Parallax Volatility Advisers first reported a position in XBI in Q2 2014 and has held it in 49 quarters since. The position peaked at $44.9M in Q2 2022. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.
- Parallax Volatility Advisers held 16,933 shares of State Street SPDR S&P Biotech ETF worth $2.68M as of Q2 2026.
- Parallax Volatility Advisers bought 3,299 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $446K.
- State Street SPDR S&P Biotech ETF made up ﹤0.01% of Parallax Volatility Advisers's portfolio in Q2 2026, its #741 holding.
- Parallax Volatility Advisers first reported a position in State Street SPDR S&P Biotech ETF in Q2 2014 and has held it in 49 quarters since.
- Parallax Volatility Advisers's State Street SPDR S&P Biotech ETF position peaked at $44.9M in Q2 2022.
- 933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.
Based on Parallax Volatility Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.